ATE491038T1 - Verfahren und nukleinsäuren zur analyse von kolonkrebs - Google Patents

Verfahren und nukleinsäuren zur analyse von kolonkrebs

Info

Publication number: ATE491038T1
Authority: AT; Austria
Prior art keywords: nucleic acids; colon cancer; cell proliferative; proliferative disorders; analyzing
Prior art date: 2002-02-27

Application number

AT03742964T

Other languages

English (en)

Inventor

Peter Adorjan

Matthias Burger

Sabine Maier

Ralf Lesche

Susan Cottrell

Suzanne Mooney

Original Assignee

Epigenomics Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-27

Filing date

2003-02-27

Publication date

2010-12-15

2003-02-27 Application filed by Epigenomics Ag filed Critical Epigenomics Ag

2010-12-15 Application granted granted Critical

2010-12-15 Publication of ATE491038T1 publication Critical patent/ATE491038T1/de

Links

238000000034 method Methods 0.000 title abstract 2
206010009944 Colon cancer Diseases 0.000 title 1
208000029742 colonic neoplasm Diseases 0.000 title 1
150000007523 nucleic acids Chemical class 0.000 title 1
102000039446 nucleic acids Human genes 0.000 title 1
108020004707 nucleic acids Proteins 0.000 title 1
210000001072 colon Anatomy 0.000 abstract 2
230000002062 proliferating effect Effects 0.000 abstract 2
230000030933 DNA methylation on cytosine Effects 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
238000003745 diagnosis Methods 0.000 abstract 1
230000004069 differentiation Effects 0.000 abstract 1
230000001973 epigenetic effect Effects 0.000 abstract 1
230000002068 genetic effect Effects 0.000 abstract 1
238000012544 monitoring process Methods 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Immunology (AREA)
Analytical Chemistry (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Pathology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Hospice & Palliative Care (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Apparatus Associated With Microorganisms And Enzymes (AREA)
Investigating Or Analysing Biological Materials (AREA)
Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT03742964T 2002-02-27 2003-02-27 Verfahren und nukleinsäuren zur analyse von kolonkrebs ATE491038T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02004551A EP1340818A1 (de)	2002-02-27	2002-02-27	Verfahren und Nukleinsäuren zur Analyse von Kolonkrebszellen
PCT/EP2003/002034 WO2003072820A2 (en)	2002-02-27	2003-02-27	Method and nucleic acids for the analysis of colon cell proliferative disorders

Publications (1)

Publication Number	Publication Date
ATE491038T1 true ATE491038T1 (de)	2010-12-15

Family

ID=27675653

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
AT03742934T ATE376596T1 (de)	2002-02-27	2003-02-13	Verfahren und nukleinsäuren zur analyse von störungen der proliferation kolorektaler zellen
AT03742964T ATE491038T1 (de)	2002-02-27	2003-02-27	Verfahren und nukleinsäuren zur analyse von kolonkrebs
AT03714760T ATE431429T1 (de)	2002-02-27	2003-02-27	Verfahren und nukleinsäuren zur analyse von kolonkrebszellen

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT03742934T ATE376596T1 (de)	2002-02-27	2003-02-13	Verfahren und nukleinsäuren zur analyse von störungen der proliferation kolorektaler zellen

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT03714760T ATE431429T1 (de)	2002-02-27	2003-02-27	Verfahren und nukleinsäuren zur analyse von kolonkrebszellen

Country Status (9)

Country	Link
US (6)	US8691503B2 (de)
EP (4)	EP1340818A1 (de)
JP (3)	JP2005518218A (de)
AT (3)	ATE376596T1 (de)
AU (3)	AU2003210265A1 (de)
CA (1)	CA2451982A1 (de)
DE (3)	DE60317045T2 (de)
ES (2)	ES2295607T3 (de)
WO (3)	WO2003072812A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9201067B2 (en) *	2003-03-05	2015-12-01	Posco	Size-controlled macromolecule
EP1340818A1 (de)	2002-02-27	2003-09-03	Epigenomics AG	Verfahren und Nukleinsäuren zur Analyse von Kolonkrebszellen
US20040029128A1 (en) *	2002-08-08	2004-02-12	Epigenomics, Inc.	Methods and nucleic acids for the analysis of CpG dinucleotide methylation status associated with the calcitonin gene
WO2005071111A1 (en) *	2004-01-23	2005-08-04	Lingvitae As	Improving polynucleotide ligation reactions
EP1730160A4 (de) *	2004-03-17	2008-04-09	Univ Johns Hopkins	Zusammensetzungen zur diagnose von neoplasie und anwendungsverfahren
EP1778865A1 (de) *	2004-06-23	2007-05-02	Epigenomics AG	Verfahren und nukleinsäuren zum nachweis der metastasierung proliferativer kolonzellerkrankungen
KR100617649B1 (ko)	2004-09-24	2006-09-04	(주)지노믹트리	대장암 특이적 발현감소 유전자의 메틸화된 프로모터를 함유하는 암 진단용 조성물 및 그 용도
WO2006039563A2 (en) *	2004-09-30	2006-04-13	Epigenomics Ag	Method for providing dna fragments derived from an archived sample
US7932027B2 (en)	2005-02-16	2011-04-26	Epigenomics Ag	Method for determining the methylation pattern of a polynucleic acid
WO2006088978A1 (en)	2005-02-16	2006-08-24	Epigenomics, Inc.	Method for determining the methylation pattern of a polynucleic acid
WO2006113770A1 (en)	2005-04-15	2006-10-26	Epigenomics Ag	A method for providing dna fragments derived from a remote sample
US20100143899A1 (en) *	2005-05-17	2010-06-10	University Of Vermont And State Agricultural College	Methods and products for diagnosing cancer
US20080076134A1 (en) *	2006-09-21	2008-03-27	Nuclea Biomarkers, Llc	Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan
US8445442B2 (en) *	2007-04-26	2013-05-21	University Of Vermont And State Agricultural College	CCL18 and CCL3 methods and compositions for detecting and treating cancer
WO2009045370A2 (en)	2007-09-28	2009-04-09	Intrexon Corporation	Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
AU2008312457B2 (en) *	2007-10-19	2014-04-17	Genentech, Inc.	Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
EP2644713B1 (de) *	2007-10-23	2018-07-04	Clinical Genomics Pty Ltd	Verfahren zur Diagnose von Neoplasmen - II
KR100969692B1 (ko) *	2008-01-18	2010-07-14	한국생명공학연구원	대장암 과발현 유전자를 이용한 대장암 진단 마커
WO2010053539A2 (en) *	2008-11-05	2010-05-14	The Texas A&M University System	Methods for detecting colorectal diseases and disorders
CN102257161A (zh) *	2008-12-18	2011-11-23	皇家飞利浦电子股份有限公司	用于检测dna甲基化模式的方法
JP2014519310A (ja)	2011-02-02	2014-08-14	エクザクトサイエンシーズコーポレイション	Ｄｎａメチル化のデジタル配列分析
AU2012324545A1 (en) *	2011-10-17	2014-06-05	King Abdullah University Of Science And Technology	Composite biomarker for non-invasive screening, diagnosis and prognosis of colorectal cancer
US9598735B2 (en) *	2012-11-14	2017-03-21	JBS Science Inc.	Detection of a panel of urine DNA markers for HCC screening and disease management
EP2886659A1 (de) *	2013-12-20	2015-06-24	AIT Austrian Institute of Technology GmbH	Genmethylierung basierend auf der Diagnose von Kolorektalkrebs

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5585481A (en)	1987-09-21	1996-12-17	Gen-Probe Incorporated	Linking reagents for nucleotide probes
US5023090A (en) *	1989-08-16	1991-06-11	Levin Robert H	Topical compositions containing LYCD and other topically active medicinal ingredients for the treatment of ACNE
US5457183A (en)	1989-03-06	1995-10-10	Board Of Regents, The University Of Texas System	Hydroxylated texaphyrins
US5744101A (en)	1989-06-07	1998-04-28	Affymax Technologies N.V.	Photolabile nucleoside protecting groups
US5580722A (en) *	1989-07-18	1996-12-03	Oncogene Science, Inc.	Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
US5180808A (en) *	1989-11-27	1993-01-19	La Jolla Cancer Research Foundation	Versican core protein, nucleic acid sequences encoding the same, nucleic acid probes, anti-versican antibodies, and methods of detecting the same
US5245022A (en)	1990-08-03	1993-09-14	Sterling Drug, Inc.	Exonuclease resistant terminally substituted oligonucleotides
US5210015A (en) *	1990-08-06	1993-05-11	Hoffman-La Roche Inc.	Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5565552A (en)	1992-01-21	1996-10-15	Pharmacyclics, Inc.	Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5574142A (en)	1992-12-15	1996-11-12	Microprobe Corporation	Peptide linkers for improved oligonucleotide delivery
SE501439C2 (sv)	1993-06-22	1995-02-13	Pharmacia Lkb Biotech	Sätt och anordning för analys av polynukleotidsekvenser
US5837832A (en)	1993-06-25	1998-11-17	Affymetrix, Inc.	Arrays of nucleic acid probes on biological chips
EP0889122A3 (de)	1993-11-30	1999-03-03	McGILL UNIVERSITY	DNA Methyltransferase Inhibierung
US5597696A (en)	1994-07-18	1997-01-28	Becton Dickinson And Company	Covalent cyanine dye oligonucleotide conjugates
US5786146A (en) *	1996-06-03	1998-07-28	The Johns Hopkins University School Of Medicine	Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6017704A (en)	1996-06-03	2000-01-25	The Johns Hopkins University School Of Medicine	Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
WO1998032849A2 (en)	1997-01-29	1998-07-30	Institut Pasteur	Polynucleotide associated with the bo or bor syndrome, its corresponding polypeptide and diagnostic and therapeutic applications
DE19754482A1 (de)	1997-11-27	1999-07-01	Epigenomics Gmbh	Verfahren zur Herstellung komplexer DNA-Methylierungs-Fingerabdrücke
GB2339200B (en)	1998-06-06	2001-09-12	Genostic Pharma Ltd	Genostics
US7700324B1 (en) *	1998-11-03	2010-04-20	The Johns Hopkins University School Of Medicine	Methylated CpG island amplification (MCA)
US5958773A (en)	1998-12-17	1999-09-28	Isis Pharmaceuticals Inc.	Antisense modulation of AKT-1 expression
AU3316600A (en) *	1999-02-22	2000-09-21	Torben F. Orntoft	Gene expression in bladder tumors
US6331393B1 (en) *	1999-05-14	2001-12-18	University Of Southern California	Process for high-throughput DNA methylation analysis
DE19935772C2 (de) *	1999-07-26	2002-11-07	Epigenomics Ag	Verfahren zur relativen Quantifizierung der Methylierung von Cytosin Basen in DNA-Proben
CA2697207A1 (en) *	1999-07-30	2001-02-08	Epidauros	Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications
WO2001068912A2 (de) *	2000-03-15	2001-09-20	Epigenomics Ag	Diagnosis of diseases associated with tumor suppressor genes and oncogenes
DE10019058A1 (de)	2000-04-06	2001-12-20	Epigenomics Ag	Detektion von Variationen des DNA-Methylierungsprofils
WO2001072781A2 (en)	2000-03-28	2001-10-04	Chiron Corporation	Human genes and expression products
DE10029915B4 (de) *	2000-06-19	2005-06-16	Epigenomics Ag	Verfahren zum Nachweis von Cytosin-Methylierungen
AU2001276371A1 (en) *	2000-06-30	2002-01-14	Epigenomics Ag	Method and nucleic acids for analysing the methylation of genes implicated pharmacogenomics
DK1423528T3 (da) *	2000-09-01	2008-05-13	Epigenomics Ag	Fremgangsmåde til bestemmelse af methyleringsgraden af bestemte cytosiner i genomisk DNA i sekvenskonteksten 5-CPG-3
AU2002305051A1 (en) *	2001-03-15	2002-10-03	Clemson University	Polynucleotide encoding a gene conferring resistance to bacillus thuringiensis toxins
DE10120798B4 (de) *	2001-04-27	2005-12-29	Genovoxx Gmbh	Verfahren zur Bestimmung der Genexpression
US20030138793A1 (en)	2001-06-10	2003-07-24	Irm Llc, A Delaware Limited Liability Company	Molecular signatures of commonly fatal carcinomas
AU2003212878A1 (en) *	2002-01-30	2003-09-02	Epigenomics Ag	Identification of cell differentiation states based on methylation patterns
EP1340818A1 (de)	2002-02-27	2003-09-03	Epigenomics AG	Verfahren und Nukleinsäuren zur Analyse von Kolonkrebszellen
WO2007123892A2 (en) *	2006-04-17	2007-11-01	Arqule Inc.	Raf inhibitors and their uses

2002
- 2002-02-27 EP EP02004551A patent/EP1340818A1/de not_active Withdrawn
2003
- 2003-02-13 DE DE60317045T patent/DE60317045T2/de not_active Expired - Lifetime
- 2003-02-13 CA CA002451982A patent/CA2451982A1/en not_active Abandoned
- 2003-02-13 EP EP03742934A patent/EP1478784B1/de not_active Expired - Lifetime
- 2003-02-13 AU AU2003210265A patent/AU2003210265A1/en not_active Abandoned
- 2003-02-13 ES ES03742934T patent/ES2295607T3/es not_active Expired - Lifetime
- 2003-02-13 JP JP2003571492A patent/JP2005518218A/ja active Pending
- 2003-02-13 AT AT03742934T patent/ATE376596T1/de not_active IP Right Cessation
- 2003-02-13 US US10/482,823 patent/US8691503B2/en not_active Expired - Fee Related
- 2003-02-13 WO PCT/EP2003/001457 patent/WO2003072812A2/en not_active Ceased
- 2003-02-27 AT AT03742964T patent/ATE491038T1/de not_active IP Right Cessation
- 2003-02-27 EP EP03714760A patent/EP1478778B1/de not_active Expired - Lifetime
- 2003-02-27 US US10/506,111 patent/US20060246433A1/en not_active Abandoned
- 2003-02-27 WO PCT/EP2003/002034 patent/WO2003072820A2/en not_active Ceased
- 2003-02-27 EP EP03742964A patent/EP1481095B1/de not_active Expired - Lifetime
- 2003-02-27 AT AT03714760T patent/ATE431429T1/de not_active IP Right Cessation
- 2003-02-27 US US10/506,089 patent/US20060234224A1/en not_active Abandoned
- 2003-02-27 AU AU2003248349A patent/AU2003248349B2/en not_active Ceased
- 2003-02-27 WO PCT/EP2003/002035 patent/WO2003072821A2/en not_active Ceased
- 2003-02-27 DE DE60327600T patent/DE60327600D1/de not_active Expired - Lifetime
- 2003-02-27 DE DE60335245T patent/DE60335245D1/de not_active Expired - Lifetime
- 2003-02-27 JP JP2003571501A patent/JP2005518220A/ja active Pending
- 2003-02-27 JP JP2003571500A patent/JP2005518219A/ja active Pending
- 2003-02-27 ES ES03714760T patent/ES2325363T3/es not_active Expired - Lifetime
- 2003-02-27 AU AU2003219002A patent/AU2003219002B2/en not_active Ceased
2010
- 2010-06-04 US US12/794,449 patent/US9988683B2/en not_active Expired - Lifetime
2014
- 2014-02-21 US US14/186,984 patent/US20140179563A1/en not_active Abandoned
- 2014-11-25 US US14/553,566 patent/US20150275312A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2003219002B2 (en)	2008-04-24
ATE376596T1 (de)	2007-11-15
WO2003072821A2 (en)	2003-09-04
EP1481095B1 (de)	2010-12-08
AU2003248349A1 (en)	2003-09-09
WO2003072820A2 (en)	2003-09-04
JP2005518220A (ja)	2005-06-23
US8691503B2 (en)	2014-04-08
US20150275312A1 (en)	2015-10-01
EP1478778B1 (de)	2009-05-13
WO2003072812A2 (en)	2003-09-04
DE60317045D1 (de)	2007-12-06
AU2003248349B2 (en)	2008-05-01
WO2003072820A3 (en)	2004-04-08
EP1340818A1 (de)	2003-09-03
CA2451982A1 (en)	2003-09-04
DE60327600D1 (de)	2009-06-25
WO2003072812A3 (en)	2003-10-23
US9988683B2 (en)	2018-06-05
ES2325363T3 (es)	2009-09-02
WO2003072821A3 (en)	2004-04-01
US20140179563A1 (en)	2014-06-26
EP1478784A2 (de)	2004-11-24
DE60317045T2 (de)	2008-08-07
EP1478778A2 (de)	2004-11-24
EP1481095A2 (de)	2004-12-01
US20060234224A1 (en)	2006-10-19
US20050003463A1 (en)	2005-01-06
JP2005518218A (ja)	2005-06-23
US20060246433A1 (en)	2006-11-02
ATE431429T1 (de)	2009-05-15
US20110046005A1 (en)	2011-02-24
ES2295607T3 (es)	2008-04-16
DE60335245D1 (de)	2011-01-20
JP2005518219A (ja)	2005-06-23
EP1478784B1 (de)	2007-10-24
AU2003219002A1 (en)	2003-09-09
AU2003210265A1 (en)	2003-09-09

Legal Events

Date	Code	Title	Description
2011-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE431429T1 (de)	2009-05-15	Verfahren und nukleinsäuren zur analyse von kolonkrebszellen
WO2002077272A3 (en)	2003-11-27	Methods and nucleic acids for the analysis of hematopoietic cell proliferative disorders
WO2002002808A3 (en)	2003-09-04	Method and nucleic acids for the analysis of astrocytomas
DE60126593D1 (de)	2007-03-29	Diagnose von mit apoptose assoziierten erkrankungen mittels ermittlung des methylierungszustandes von apoptose-assozierten genen
ATE437962T1 (de)	2009-08-15	Verfahren für die behandlung von proliferativen erkrankungen von brustzellen
WO2003052135A3 (en)	2004-02-12	Method and nucleic acids for the analysis of a lung cell proliferative disorder
WO2004020662A3 (en)	2004-08-26	Method and nucleic acids for the analysis of breast cell proliferative disorders
DE602006003012D1 (de)	2008-11-20	Verfahren und Nukleinsäuren für die Analyse von zellulären Proliferationsstörungen
WO2005059172A3 (en)	2005-12-08	Method and nucleic acids for the improved treatment of breast cell proliferative disorders
WO2001068911A3 (en)	2002-11-28	Diagnosis of diseases associated with the cell cycle
ATE451611T1 (de)	2009-12-15	Verfahren zum nachweis einzelner nukleotidpolymorphismen (snp) und punktmutationen in genen
WO2003014388A3 (en)	2003-11-06	Method and nucleic acids for the analysis of colon cancer
WO2005001142A3 (en)	2005-12-15	Methods and nucleic acids for the analysis of colorectal cell proliferative disorders
WO2005001141A3 (en)	2005-11-17	Methods and nucleic acids for analyses of colorectal cell proliferative disorders
WO2002103042A3 (en)	2003-10-30	Method and nucleic acids for the differentiation of prostate tumors
WO2003044226A3 (en)	2004-03-11	Method and nucleic acids for the analysis of a lymphoid cell proliferative disorder
US11034996B2 (en)	2021-06-15	Nucleic acid sequence and capture by formation of an abasic site-derived cross-link
ATE494390T1 (de)	2011-01-15	Verfahren und nukleinsäuren zur analyse von störungen der proliferation von kolonzellen
EP3348650B1 (de)	2020-12-23	Kit und verfahren zum nachweis von einzelnukleotid-polymorphismus
ATE350489T1 (de)	2007-01-15	Diagnose von mit humos assoziierten krankheiten
WO2002103041A3 (en)	2003-10-23	Method and nucleic acids for the differentiation of prostate and renal carcinomas
EP1358345B1 (de)	2009-10-21	Multitemperature "single strand conformation polymorphism" (msscp)